Interferon-beta-1b increases serum interleukin-12 p40 levels in primary progressive multiple sclerosis patients.
Neurosci Lett
; 326(2): 125-8, 2002 Jun 28.
Article
em En
| MEDLINE
| ID: mdl-12057844
ABSTRACT
Serum levels of interleukin-12 heterodimer (IL-12p70) and its homodimeric subunit (IL-12p40) were analyzed by enzyme-linked immunosorbent assay in 18 patients with primary progressive multiple sclerosis (MS) during 3 months before and 3 months under treatment with interferon-beta-1b (IFNbeta-1b, Betaferon(), eight million units (MIU) every other day subcutaneously). Median IL-12p40 levels in MS patients before treatment (66.5 and 63.9 pg/ml) were not elevated compared to 18 healthy controls. IL-12p40 significantly increased during treatment (P<0.0001, median 105.3 pg/ml after 1 month and 95.3 pg/ml after 3 months). Detectable serum levels of IL-12p70 before therapy were only found in one patient. IL-12p70 did not increase during treatment. These data show that immunological processes may also play a role in primary progressive MS and that IFNbeta-1b has an immunomodulating effect in this particular MS subtype.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Adjuvantes Imunológicos
/
Interferon beta
/
Interleucina-12
/
Esclerose Múltipla Crônica Progressiva
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Neurosci Lett
Ano de publicação:
2002
Tipo de documento:
Article
País de afiliação:
Alemanha